Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...

Pirtobrutinib is currently approved for the treatment of patients with CLL/SLL who have received at least 2 prior lines of therapy.

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial ...

Bristol Myers BMY recently announced that it will acquire privately held biotechnology company Orbital Therapeutics for $1.5 ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to UB-VV111 for the treatment of ...

At a memorial service in 2022, veteran Air Force Capt. Monte Watts bumped into a fellow former Minuteman III nuclear missile ...

Researchers at Weill Cornell Medicine and the University of Adelaide have developed GoT-Multi, a tool that tracks multiple ...

The FDA has granted fast track designation to UB-VV111 for the treatment of relapsed/refractory large B-cell lymphoma (LBCL) following 2 or more prior lines of therapy and relapsed/refractory chronic ...

日本血液学会（JSH）第87届年会于2025年10月10日至12日在日本神户盛大召开。本次大会上，一项评估亚太地区套细胞淋巴瘤（MCL）患者接受二线或三线BTK抑制剂序贯治疗的疗效研究数据得以公布。哈尔滨血液病肿瘤研究所马军教授亲赴JSH现场，第一时 ...

The company’s market value has increased by approximately $3.3 billion over the past 5 days, bringing its current market ...